

WR:wr 8/15/02 134862
PATENTAttorney Reference Number 4239-55278
Application Number 09/622,635

C1
CONT'D

array can be formed from cell suspensions such that identical multiple copies of an array are formed, in which corresponding positions in the copies of the array have samples from the same or similar specimen. The results of the different biological analyses are compared to determine if there are correlations between the results of the different biological analyses at each assigned location. In some embodiments, the specimens may be tissue specimens from different tumors, which are subjected to multiple parallel molecular (including genetic and immunological) analyses. The results of the parallel analyses are then used to detect common molecular characteristics of the tumor type, which can subsequently be used in the diagnosis or treatment of the disease. The biological characteristics of the tissue can be correlated with clinical or other information, to detect characteristics associated with the tissue, such as susceptibility or resistance to particular types of drug treatment. Other examples of suitable tissues which can be placed in the matrix include tissue from transgenic or model organisms, or cellular suspensions (such as cytological preparations or specimens of liquid malignancies or cell lines).

REMARKS

The specification has been amended herein to insert the Abstract, originally included in the first page of the international application, as the last page of the specification.

If any further matters remain to be discussed regarding this application, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By William D. Noonan
William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

WR:wr 8/15/02 134862
PATENT

Attorney Reference Number 4239-55278
Application Number 09/622,635

**Marked-up Version of Amended Abstract
Pursuant to 37 C.F.R. §§ 1.121(b)-(c)**

In the Abstract:

Please see the marked-up version of page 57 of the specification, the Abstract, as attached hereto.